Sanofi is paying €23m upfront to Belgium-based Ablynx NV for access to the latter company's Nanobody-based therapeutic platform; the pair will develop novel treatments for various immune mediated inflammatory diseases.
Ablynx Adds Sanofi To Its List Of Big Pharma Partners
Sanofi is the latest big pharma, following on from Merck & Co., AbbVie and others, to team up with Belgian Nanobody drug developer Ablynx.
